FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma By Ogkologos - August 14, 2025 643 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR Five-Year Survival Outcomes with Neoadjuvant Therapy in Melanoma Demonstrate that Neoadjuvant ICIs Exceeded Adjuvant Benchmarks Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib MOST POPULAR Foodie Fridays: An Ode to Summer Tomatoes July 2, 2021 HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy... September 29, 2025 Consuming Poultry Could Lower Your Breast Cancer Risk As Much As... August 22, 2019 Clinical and Biological Activity of Patritumab Deruxtecan in Patients with HR-positive,... June 5, 2023 Load more HOT NEWS Zanidatamab Demonstrates Meaningful Clinical Benefit with a Manageable Safety Profile in... Androgen Receptor Pathway Inhibitors Outperform Taxanes in Patients with mCRPC with... 6 Things to Know About Regrowing and Caring for Your Hair... Tips from Your Cancer Care Team – Coping with Treatment During...
